666 related articles for article (PubMed ID: 24906029)
1. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
[TBL] [Abstract][Full Text] [Related]
2. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
Morris JH; Bohm NM; Nemecek BD; Crawford R; Kelley D; Bhasin B; Nietert PJ; Velez JCQ
Am J Kidney Dis; 2018 Jun; 71(6):772-782. PubMed ID: 29478867
[TBL] [Abstract][Full Text] [Related]
3. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C;
N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone.
Han SW; Yi JH; Kang KP; Kim HY; Kim SW; Choi HY; Ha SK; Kim GH; Kim YW; Jeong KH; Shin SK; Kim HJ
J Korean Med Sci; 2018 Apr; 33(15):e112. PubMed ID: 29629516
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials.
Dasta JF; Chiong JR; Christian R; Lin J
Hosp Pract (1995); 2012 Feb; 40(1):7-14. PubMed ID: 22406878
[TBL] [Abstract][Full Text] [Related]
6. [The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia].
Li L; Bai H; Zhu WL;
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):936-40. PubMed ID: 22321279
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
Nemerovski C; Hutchinson DJ
Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH.
Soupart A; Coffernils M; Couturier B; Gankam-Kengne F; Decaux G
Clin J Am Soc Nephrol; 2012 May; 7(5):742-7. PubMed ID: 22403276
[TBL] [Abstract][Full Text] [Related]
9. Open-label, multicenter, dose-titration study to determine the efficacy and safety of tolvaptan in Japanese patients with hyponatremia secondary to syndrome of inappropriate secretion of antidiuretic hormone.
Arima H; Goto K; Motozawa T; Mouri M; Watanabe R; Hirano T; Ishikawa SE
Endocr J; 2021 Jan; 68(1):17-29. PubMed ID: 32863282
[TBL] [Abstract][Full Text] [Related]
10. A retrospective study on tolvaptan prescription in clinical practice in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) using the Japanese claims database.
Hagiwara D; Matsukawa M; Tasaki J; Nakamura Y; Arima H
Endocr J; 2023 Dec; 70(12):1195-1205. PubMed ID: 37914256
[TBL] [Abstract][Full Text] [Related]
11. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
Vaghasiya RP; DeVita MV; Michelis MF
Int Urol Nephrol; 2012 Jun; 44(3):865-71. PubMed ID: 21607553
[TBL] [Abstract][Full Text] [Related]
12. Low-dose tolvaptan PK/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults.
Shoaf SE; Bricmont P; Dandurand A
Eur J Clin Pharmacol; 2017 Nov; 73(11):1399-1408. PubMed ID: 28803333
[TBL] [Abstract][Full Text] [Related]
13. Using Tolvaptan to Treat Hyponatremia: Results from a Post-authorization Pharmacovigilance Study.
Estilo A; McCormick L; Rahman M
Adv Ther; 2021 Dec; 38(12):5721-5736. PubMed ID: 34693505
[TBL] [Abstract][Full Text] [Related]
14. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis.
Cárdenas A; Ginès P; Marotta P; Czerwiec F; Oyuang J; Guevara M; Afdhal NH
J Hepatol; 2012 Mar; 56(3):571-8. PubMed ID: 22027579
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH.
Bordi P; Tiseo M; Buti S; Regolisti G; Ardizzoni A
Tumori; 2015 Apr; 101(2):e51-3. PubMed ID: 25702667
[TBL] [Abstract][Full Text] [Related]
16. In-patient Tolvaptan use in SIADH: care audit, therapy observation and outcome analysis.
Humayun MA; Cranston IC
BMC Endocr Disord; 2017 Nov; 17(1):69. PubMed ID: 29110656
[TBL] [Abstract][Full Text] [Related]
17. Tolvaptan.
Plosker GL
Drugs; 2010 Mar; 70(4):443-54. PubMed ID: 20205486
[TBL] [Abstract][Full Text] [Related]
18. [Lower doses of tolvaptan in hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion].
Sánchez Sobrino P; Fernández Catalina P; Lorenzo Solar M; Rego Iraeta A
Med Clin (Barc); 2015 Aug; 145(3):138-9. PubMed ID: 25543222
[No Abstract] [Full Text] [Related]
19. Tolvaptan in hospitalized cancer patients with hyponatremia: a double-blind, randomized, placebo-controlled clinical trial on efficacy and safety.
Salahudeen AK; Ali N; George M; Lahoti A; Palla S
Cancer; 2014 Mar; 120(5):744-51. PubMed ID: 24895288
[TBL] [Abstract][Full Text] [Related]
20. Prompt efficacy of tolvaptan in treating hyponatremia of syndrome of inappropriate secretion of antidiuretic hormone (SIADH) closely associated with rupture of a gastric artery aneurysm.
Yamashita T; Yoshida M; Yamada H; Asano T; Aoki A; Ikoma A; Kusaka I; Kakei M; Ishikawa SE
Intern Med; 2014; 53(8):845-9. PubMed ID: 24739604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
